Sana Biotechnology (SANA) Operating Leases (2020 - 2026)

Sana Biotechnology's Operating Leases history runs 7 years deep, the most recent figure standing at $60.4 million for Q1 2026.

• In Q1 2026, Operating Leases fell 22.81% year-over-year to $60.4 million; the TTM figure through Mar 2026 stood at $60.4 million (down 22.81% YoY), while the FY2025 annual figure was $63.9 million, down 21.72% from the prior year.
• Operating Leases came in at $60.4 million for Q1 2026 at Sana Biotechnology, down from $63.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $103.0 million in Q2 2022 to a low of $60.4 million in Q1 2026.
• A 5-year average of $86.4 million and a median of $88.6 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases jumped 55.65% in 2022 and declined 22.81% in 2026, its largest moves.
• Sana Biotechnology's Operating Leases stood at $95.9 million in 2022, then decreased by 5.17% to $90.9 million in 2023, then decreased by 10.16% to $81.7 million in 2024, then dropped by 21.72% to $63.9 million in 2025, then declined by 5.43% to $60.4 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $60.4 million, $63.9 million, and $67.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison